SELLAS Life Sciences Group Inc (SLS) concluded trading on Wednesday at a closing price of $1.70, with 5.1 million shares of worth about $8.67 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 28.79% during that period and on May 21, 2025 the price saw a loss of about -12.37%. Currently the company’s common shares owned by public are about 99.78M shares, out of which, 97.71M shares are available for trading.
Stock saw a price change of 12.58% in past 5 days and over the past one month there was a price change of 31.78%. Year-to-date (YTD), SLS shares are showing a performance of 63.46% which increased to 16.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.77 but also hit the highest price of $1.95 during that period. The average intraday trading volume for SELLAS Life Sciences Group Inc shares is 1.62 million. The stock is currently trading 6.42% above its 20-day simple moving average (SMA20), while that difference is up 27.04% for SMA50 and it goes to 38.68% higher than SMA200.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) currently have 99.78M outstanding shares and institutions hold larger chunk of about 14.33% of that.
The stock has a current market capitalization of $169.62M and its 3Y-monthly beta is at 2.27. It has posted earnings per share of -$0.39 in the same period. It has Quick Ratio of 4.64 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SLS, volatility over the week remained 12.21% while standing at 9.94% over the month.
Analysts are in expectations that SELLAS Life Sciences Group Inc (SLS) stock would likely to be making an EPS of -0.08 in the current quarter, while forecast for next quarter EPS is -0.09 and it is -0.38 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.1 which is -0.06 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.13 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 33.00% while it is estimated to decrease by -11.94% in next year. EPS is likely to grow at an annualized rate of 50.68% for next 5-years, compared to annual growth of 45.94% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on July 21, 2021 offering an Overweight rating for the stock and assigned a target price of $18 to it. On April 02, 2018, H.C. Wainwright Initiated their recommendations, while on March 19, 2018, Maxim Group Upgrade their ratings for the stock with a price target of $13.
